The HPTN 052 clinical trial, an international HIV prevention trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), found that if HIV-infected heterosexual individuals begin taking antiretroviral medicines when their immune systems are relatively healthy (as opposed to delaying therapy until the disease has advanced), they are 96 percent less likely to transmit the virus to their uninfected partners.